Sangart was granted orphan drug designation by the FDA for its drug candidate, MP4CO, for the treatment of acute painful sickling crises in patients with sickle cell disease. MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. CO stabilizes hemoglobin S, an abnormal type of hemoglobin, and prevents sickling of red blood cells. The addition of MP4CO to existing treatment protocols may alleviate pain associated with a sickle cell crisis and potentially reduce the duration of a crisis.
For more information call (858) 450-2400 or visit www.sangart.com.